Research conducted at Zagazig University, Zagazig, Egypt found that a single injection of botulinum toxin (BTX) is a safe and effective treatment option for resistant localized plaque psoriasis in comparison to intralesional 5-fluorouracil (5-FU).
“More studies are required to further prove the efficacy of BTX in the treatment of plaque psoriasis,” the study’s authors concluded.
Investigators conducted a comparative study to evaluate the safety and efficacy of intradermal BTX as a treatment for plaque psoriasis. The findings were published online ahead of print in the Journal of Cosmetic Dermatology (June 19, 2021).
Thirty-five patients with chronic plaque psoriasis were treated with either intradermal BTX or 5-FU to each of two bilaterally symmetrical psoriatic plaque lesions.
Investigators measured the outcomes using the following criteria: the sum of erythema, scaling and induration scores as well as the clearing percentage of the target plaque lesion assessed by two blinded observers.
The results showed that the response rate was 85% on the BTX treatment site and 90% on the 5-FU site. The authors note there was no significant difference on either site in terms of clinical response or side effects. The recurrence rate was 15% on both sites.